A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)

NCT02029157 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

386

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Cancer

Interventions

DRUG: ARQ197
DRUG: Placebo

Sponsor

Kyowa Kirin Co., Ltd.